Cancer News and Research

Latest Cancer News and Research

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for vaccines, announced today that it has entered into a license agreement for the supply of MicronJet600, its microneedle delivery device, to Circassia Pharmaceuticals plc. (Oxford, UK), a specialty biopharmaceutical company focused on the allergy market.

6 May 2015

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

In Africa, cancer kills more people than HIV/AIDS, malaria and tuberculosis combined. Approximately 40 percent of cancer cases can be prevented and 40 percent can be cured with the right treatment. Together with Elekta, ministries of health in almost a dozen African nations are working to build up their radiation therapy infrastructures and save lives.

From Elekta 6 May 2015

CCM and MD Anderson partner to improve cancer care in China, Singapore

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.

6 May 2015

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

Partners congratulate researchers on forming new biotechnology company

The Children's Hospital of Eastern Ontario, The Ottawa Hospital, the University of Ottawa and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient's own immune system.

6 May 2015

Researcher reports possible existence of sixth DNA base

DNA (deoxyribonucleic acid) is the main component of our genetic material. It is formed by combining four parts: A, C, G and T (adenine, cytosine, guanine and thymine), called bases of DNA combine in thousands of possible sequences to provide the genetic variability that enables the wealth of aspects and functions of living beings.

6 May 2015

Luxembourg biologists provide complete image of human 'miRNome' in blood samples

In an elaborate study, biologists of the University of Luxembourg have found out that small molecules named microRNAs are, against many hopes, not yet suitable for early diagnosis of skin cancer, as well as supposedly for other types of cancer, in blood samples. For the first time they analysed all microRNAs in the serum of healthy people and thus provided a first complete image of the human "miRNome" in blood samples, in reference to the better-known "genome".

6 May 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.

6 May 2015

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

TWO cutting-edge cancer treatments using targeted radioactive therapy injections to destroy cancer cells are now being offered to patients with rare neuroendocrine tumours and patients with prostate cancer at Weston Park Hospital.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

New MGH-developed technology may extend benefits of MRI in patients with implanted devices

New technology developed at the Martinos Center for Biomedical Imaging at Massachusetts General Hospital may extend the benefits of magnetic resonance imaging (MRI) to many patients whose access to MRI is currently limited.

6 May 2015

Automated PoCyton cytometer effective for counting cancer cells

Biological and medical scientists have been using flow cytometry to count cancer cells for the past 40 years. But the large instruments are expensive and can only be operated by trained personnel. By contrast the PoCyton cytometer developed by Fraunhofer researchers is cheap to produce, no bigger than a shoebox, and automated.

6 May 2015

Study offers new insights into construction of nuclear pores in nuclear envelope

In a recent study, a team of researchers led by Alwin Köhler at the Max F. Perutz Laboratories (MFPL) belonging to the University of Vienna and the Medical University of Vienna offer new insights into how nuclear pores are constructed in the nuclear envelope.

6 May 2015

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.

6 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

New study finds high levels of HCV infection among HIV-infected people across Africa

A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

6 May 2015

Relaxation response has significant impact on patients with gastrointestinal disorders

A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.

6 May 2015

1 in 5 people to develop heart failure in developed countries

One person in five is expected to develop heart failure in developed countries, a disease with no cure but which is largely preventable.

6 May 2015

Cancer News and Research

Latest Cancer News and Research

Scientists uncover new pharmaceutical strategy for treating melanoma

NanoPass signs license agreement for supply of MicronJet600 device to Circassia

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

CCM and MD Anderson partner to improve cancer care in China, Singapore

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

Partners congratulate researchers on forming new biotechnology company

Researcher reports possible existence of sixth DNA base

Luxembourg biologists provide complete image of human 'miRNome' in blood samples

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of gastric cancers

Weston Park Hospital offers two cutting-edge treatments for rare cancer tumours, prostate cancer

First patient receives new 'resistance-busting' experimental skin cancer drug

New MGH-developed technology may extend benefits of MRI in patients with implanted devices

Automated PoCyton cytometer effective for counting cancer cells

Study offers new insights into construction of nuclear pores in nuclear envelope

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

New study finds high levels of HCV infection among HIV-infected people across Africa

Relaxation response has significant impact on patients with gastrointestinal disorders

1 in 5 people to develop heart failure in developed countries

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in